Skip navigation
Watchlist Sponsored By :

Current DateTime: 06:30:54 04 Sep 2008
LinksList Documentid: 24355697

Current DateTime: 06:30:54 04 Sep 2008
LinksList Documentid: 24890560
  • Balancing Act: Credit & Debt

      Managing one's credit and debt has become a high-stakes, high-anxiety balancing act. Here's a guide to help you deal with it.

  • Fannie & Freddie Fallout

      The mortgage market meltdown ensnares two financial giants, raising questions about the health of the nation's financial system.

  • Fat Cat Living

      If you have the kind of money to live the high life and enjoy the high end, here's how to spend it, invest it and save it.

By Andrew Fisher | 21 Apr 2008 | 10:46 AM ET
Font size:

Picks and Pans

Merck's [MRK  Loading...      ()   ] revenues were light, but market reaction was positive.  Eli Lilly's [LLY  Loading...      ()   ] earnings were up sharply, but still disappointed the Street.  So how does an investor play the results?  Last week, Barbara Ryan of Deutsche Bank was looking for a "buy" in Merck and a "hold" in Eli Lilly, a call that was right on the money. On Monday, she offered CNBC her pharma insights and picks.

Outlook:

Why did Merck meet expectations with soft revenues?

"When we look at the major products that Merck sells, and what's really important to its future, those did very, very well," Ryan told CNBC.  "From that perspective, we're not concerned about the revenues."

Merck was also able to survive problems with Vytorin and Zetia, the cholesterol drugs that are part of its joint venture with Schering-Plough [SGP  Loading...      ()   ].  Ryan says those problems are more likely to impact Schering-Plough.

"Merck is predicting that profits in that joint venture, which were about $2 billion each for Merck and Schering-Plough last year, are going to be down $700+ million this year," she said.

More Recommendations:

Ryan is also downbeat about Wyeth [WYE  Loading...      ()   ].

"They...are dealing with a fair amount of generic competition, notably for their ulcer drug Protonix, so that will put pressure on their business," she said.

In addition to Merck, she recommends Pfizer [PFE  Loading...      ()   ] and Bristol-Myers [BMY  Loading...      ()   ].

"Bristol-Myers...is going to benefit from strength in their existing product portfolio, as well as a major restructuring initiative," she explained.

Disclosures:

Ryan does not personally own Merck shares, but her firm does.  Deutsche Bank also owns Eli Lilly shares, Lilly is an investment banking client, and Deutsche Bank has received non-investment banking related compensation from Eli Lilly within the past year.

Disclaimer

© 2008 CNBC.com

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis